Silvant Capital Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.74M | Hold |
21,833
| – | – | 0.1% | 113 |
|
|
2025
Q1 | $2.41M | Hold |
21,833
| – | – | 0.11% | 112 |
|
|
2024
Q4 | $2.98M | Hold |
21,833
| – | – | 0.12% | 103 |
|
|
2024
Q3 | $2.52M | Hold |
21,833
| – | – | 0.11% | 112 |
|
|
2024
Q2 | $3.01M | Buy |
21,833
+3,539
| +19% | +$487K | 0.13% | 100 |
|
|
2024
Q1 | $2.52M | Hold |
18,294
| – | – | 0.12% | 105 |
|
|
2023
Q4 | $2.41M | Hold |
18,294
| – | – | 0.13% | 103 |
|
|
2023
Q3 | $2.06M | Hold |
18,294
| – | – | 0.12% | 105 |
|
|
2023
Q2 | $1.73M | Hold |
18,294
| – | – | 0.1% | 119 |
|
|
2023
Q1 | $1.85M | Hold |
18,294
| – | – | 0.12% | 109 |
|
|
2022
Q4 | $2.19M | Buy |
+18,294
| New | +$2.19M | 0.15% | 106 |
|
|
2019
Q2 | – | Sell |
-3,038
| Closed | -$268K | – | 340 |
|
|
2019
Q1 | $268K | Hold |
3,038
| – | – | 0.05% | 164 |
|
|
2018
Q4 | $217K | Sell |
3,038
-995
| -25% | -$71.1K | 0.04% | 169 |
|
|
2018
Q3 | $496K | Hold |
4,033
| – | – | 0.06% | 126 |
|
|
2018
Q2 | $396K | Hold |
4,033
| – | – | 0.05% | 136 |
|
|
2018
Q1 | $334K | Buy |
+4,033
| New | +$334K | 0.04% | 156 |
|